Alumis Inc. (NASDAQ:ALMS) Director Acquires $112,244.88 in Stock

Alumis Inc. (NASDAQ:ALMS) Director Alan Colowick acquired 16,104 shares of the business’s stock in a transaction dated Tuesday, April 1st. The stock was acquired at an average price of $6.97 per share, with a total value of $112,244.88. Following the completion of the transaction, the director now directly owns 16,104 shares of the company’s stock, valued at approximately $112,244.88. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Alumis Stock Up 17.7 %

Alumis stock opened at $10.05 on Friday. The company has a fifty day simple moving average of $5.52 and a 200-day simple moving average of $8.22. Alumis Inc. has a 52-week low of $3.18 and a 52-week high of $13.53.

Hedge Funds Weigh In On Alumis

A number of institutional investors and hedge funds have recently bought and sold shares of ALMS. Tang Capital Management LLC lifted its stake in Alumis by 40.6% in the 4th quarter. Tang Capital Management LLC now owns 600,000 shares of the company’s stock worth $4,716,000 after purchasing an additional 173,406 shares in the last quarter. Foresite Capital Management V LLC increased its holdings in shares of Alumis by 3.5% in the fourth quarter. Foresite Capital Management V LLC now owns 5,779,348 shares of the company’s stock valued at $45,426,000 after purchasing an additional 194,459 shares during the last quarter. BNP Paribas Financial Markets lifted its position in Alumis by 1,257.0% during the fourth quarter. BNP Paribas Financial Markets now owns 34,835 shares of the company’s stock worth $274,000 after buying an additional 32,268 shares in the last quarter. Ally Bridge Group NY LLC boosted its stake in Alumis by 6.4% during the fourth quarter. Ally Bridge Group NY LLC now owns 445,259 shares of the company’s stock worth $3,500,000 after buying an additional 26,843 shares during the last quarter. Finally, Foresite Capital Management VI LLC purchased a new stake in Alumis in the 4th quarter valued at $33,033,000.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Alumis in a report on Thursday, March 20th. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of Alumis in a research report on Wednesday, March 26th. Finally, Oppenheimer initiated coverage on shares of Alumis in a research report on Thursday, January 30th. They set an “outperform” rating and a $32.00 price target for the company. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Alumis has an average rating of “Buy” and an average price target of $26.00.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.